Function Health is a technology company.
Function Health has raised $53.0M across 1 funding round.
Function Health has raised $53.0M in total across 1 funding round.
Function Health has raised $53.0M in total across 1 funding round.
Function Health's investors include Forerunner Ventures, KdT Ventures, NFX, Pioneer Fund, RX3 Growth Partners, VZVC, John Legend, Kevin Hart, Mei Z., Whitney Cummings.
# Function Health: High-Level Overview
Function Health is a membership-based healthcare technology platform that democratizes preventive health screening through direct-to-consumer lab testing and AI-powered insights.[1] Founded in 2021 and headquartered in Austin, Texas, the company operates a mission centered on empowering individuals to "live 100 healthy years" by providing access to comprehensive health data and personalized guidance.[1][2] Rather than performing tests itself, Function acts as a technology intermediary that coordinates with third-party laboratory providers like Quest Diagnostics, allowing consumers to access over 100 biomarkers—roughly five times the testing depth of a standard annual physical—for $499 annually, with optional advanced imaging add-ons.[1][3]
The company serves health-conscious consumers and increasingly employers seeking preventive diagnostic capabilities for their workforce. Function solves a critical gap in modern healthcare: the lack of accessible, proactive screening that catches disease early before symptoms emerge. With over 100,000 members and a 200,000-person waitlist as of 2024, the platform has facilitated over 5 million lab tests and documented cases of early cancer detection and cardiovascular risk identification.[1][3] The company was valued at $2.5 billion in its most recent financing round in November 2025 and raised $298 million in that funding announcement.[1][4]
Function Health was founded in 2021 by Mark Hyman (Chief Medical Officer and co-founder of Cleveland Clinic's Center for Functional Medicine), Jonathan Swerdlin (CEO and repeat founder), Pranitha Patil (COO, former health strategy lead at Accenture), Mike Nemke (CTO, former U.S. Army Green Beret and AI engineer), Seth Weisfeld (CPO, former AI product designer at Meta), and Daniel Swerdlin.[1][3]
The founding team's composition reflects a deliberate blend of medical expertise, entrepreneurial experience, and technical depth. Hyman brought decades of functional medicine credibility, while Swerdlin had already built and scaled companies. The team's motivation stemmed from personal health experiences—Swerdlin himself used Function to heal through data-driven insights—and frustration with reactive, symptom-chasing healthcare.[2][3] This mission-driven origin contrasts sharply with many health-tech startups; Function was built by people who had experienced healthcare's shortcomings firsthand.
Early traction was substantial: by 2023, the company had completed over 3 million lab tests, and by 2024, it had accumulated over 1 million data points from its initial cohort of 10,000 members.[1] This rapid scaling demonstrated strong product-market fit among consumers willing to pay for preventive health visibility.
Function Health sits at the intersection of three powerful trends: the longevity economy, consumer health empowerment, and AI-driven personalized medicine. As healthcare systems remain reactive and fragmented, Function capitalizes on growing consumer demand for preventive insights and ownership of health data. The company's timing is fortuitous—advances in AI make sense-making of complex biomarker data feasible at scale, while direct-to-consumer models have proven viable in adjacent health categories.
The company also influences the broader ecosystem by normalizing frequent, comprehensive lab testing as a consumer expectation rather than a luxury. By building a large dataset of healthy individuals' biomarkers, Function is creating a valuable resource for longevity research and potentially shifting how the healthcare industry thinks about prevention. Its partnership with the NBPA signals that even traditionally conservative institutional buyers (professional sports organizations) now see value in granular health monitoring.
However, Function operates in a landscape where evidence for some of its screening recommendations—particularly cancer and coronary artery calcium testing for low-risk populations—remains limited.[4] This positions the company at the frontier of preventive medicine, where consumer enthusiasm has outpaced clinical consensus.
Function Health is executing a compelling thesis: that democratized access to comprehensive health data, paired with AI interpretation, can shift healthcare from reactive treatment to proactive prevention. The company's $2.5 billion valuation and $298 million recent raise reflect investor confidence in this vision, and its 200,000-person waitlist suggests demand far exceeds current supply.
The next phase will likely involve scaling institutional partnerships (employers, insurers, health systems) while deepening its AI capabilities—the newly announced chatbot for personalized recommendations signals this direction. The critical challenge ahead is publishing rigorous clinical evidence that Function's screening approach improves long-term health outcomes, particularly for low-risk populations. Without this validation, the company risks being perceived as a wellness luxury rather than a genuine healthcare innovation.
If Function can bridge the gap between consumer enthusiasm and clinical evidence, it could reshape how millions approach preventive health—and potentially influence the trillion-dollar healthcare system to embrace earlier, more comprehensive screening as standard practice.
Function Health has raised $53.0M across 1 funding round. Most recently, it raised $53.0M Series A in June 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2024 | $53.0M Series A | Forerunner Ventures, KdT Ventures, NFX, Pioneer Fund, RX3 Growth Partners, VZVC, John Legend, Kevin Hart, Mei Z., Whitney Cummings |